Like a great orchestra, your brain relies on the perfect coordination of many elements to function properly. And if one of those elements is out of sync, it affects the entire ensemble. In Alzheimer’s disease, for instance, damage to specific neurons can alter brainwave rhythms and cause a loss of cognitive functions.
One type of neuron, called inhibitory interneuron, is particularly important for managing brain rhythms. It’s also the research focus of a laboratory led by Jorge Palop, PhD, assistant investigator at the Gladstone Institutes. In a study published in Neuron, Palop and his collaborators uncovered the therapeutic benefits of genetically improving these interneurons and transplanting them into the brain of a mouse model of Alzheimer’s disease.
Interneurons control complex networks between neurons, allowing them to send signals to one another in a harmonized way. You can think of inhibitory interneurons as orchestra conductors. They create rhythms in the brain to instruct the players—excitatory neurons—when to play and when to stop. An imbalance between these two types of neurons creates disharmony and is seen in multiple neurological and psychiatric disorders, including Alzheimer’s disease, epilepsy, schizophrenia, and autism.
A Brain without a Conductor
Palop’s previous studies showed that, in mouse models of Alzheimer’s, the inhibitory interneurons do not work properly. So, the rhythms that organize the excitatory cells are disturbed and fail to function harmoniously, causing an imbalance in brain networks. This, in turn, affects memory formation and can lead to epileptic activity, which is often observed in patients with Alzheimer’s disease.
His team found a way to reengineer inhibitory interneurons to improve their function. They showed that these enhanced interneurons, when transplanted into the abnormal brain of Alzheimer mice, can properly control the activity of excitatory cells and restore brain rhythms.
“We took advantage of the fact that transplanted interneurons can integrate remarkably well into new brain tissues, and that each interneuron can control thousands of excitatory neurons,” said Palop, who is also an assistant professor of neurology at the University of California, San Francisco. “These properties make interneurons a promising therapeutic target for cognitive disorders associated with brain rhythm abnormalities and epileptic activity.”
First, the scientists had to overcome a significant challenge. When they transplanted regular interneurons, they saw no beneficial effects, presumably because Alzheimer’s disease creates a toxic environment in the brain.
The researchers then genetically boosted the activity of inhibitory interneurons by adding a protein called Nav1.1. They discovered that the interneurons with enhanced function were able to overcome the toxic disease environment and restore brain function.
“These optimized neurons are like master conductors,” said Palop. “Even with a declining orchestra, they can restore the rhythms and harmony needed for cognitive functions.”
Conductors Engineered for Alzheimer’s Disease
The findings could eventually lead to the development of new treatment options for patients with Alzheimer’s disease.
“Besides the applications this cell engineering and transplantation approach may find in regenerative medicine, our findings support the broader concept that enhancing the function of interneurons can counteract key aspects of Alzheimer’s disease,” said Lennart Mucke, MD, director of the Gladstone Institute of Neurological Disease.
In addition to examining if the cell therapy could be translated from mice to humans, Palop and his team are working to identify potential drugs as an alternative way to enhance the function of inhibitory interneurons.
The Latest on: Alzheimer’s Disease
via Google News
The Latest on: Alzheimer’s Disease
- Possible pathway to new therapy for Alzheimer's disease on February 19, 2019 at 1:30 pm
Researchers have uncovered an enzyme and a biochemical pathway they believe may lead to the identification of drugs that could inhibit the production of beta-amyloid protein, the toxic initiator ... […]
- Takeda collaboration to boost fight against Alzheimer's and other neurodegeneration on February 19, 2019 at 1:15 pm
It is found in the brains of sufferers of more than 20 different neurodegenerative diseases, of which Alzheimer's disease is the most common. Tau pathy is increasingly thought to be an important drive... […]
- FDA: Taking blood from young donors not clinically proven to fight disease on February 19, 2019 at 1:11 pm
The agency hasn't approved plasma infusions for Alzheimer's disease, dementia, multiple sclerosis, Parkinson's disease, post‐traumatic stress disorder and heart disease, common conditions patients loo... […]
- Local Alzheimer's advocates push for continued state help on February 19, 2019 at 1:11 pm
MADISON, Wis. - Tuesday is 2019 Alzheimer’s Advocacy Day. The disease is the sixth leading cause of death in Wisconsin and the United States. More than 200 advocates are attending legislative meetings ... […]
- Alzheimer's Drug Discovery Foundation and Harrington Discovery Institute Invite Applications for 2019 ADDF-Harrington Scholar Award on February 19, 2019 at 12:49 pm
The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, or slow Alzheimer's disease or related dementias. This year's RFP seeks pr... […]
- Research finds ethnoracial differences in Alzheimer's disease on February 19, 2019 at 8:10 am
A team of Mayo Clinic researchers found Hispanic-American patients with Alzheimer's tend to survive significantly longer with the disease than other ethnoracial groups, according to a study in ... […]
- Charlottesville Church to Host Conference on Alzheimer's Disease on February 19, 2019 at 7:26 am
Pilgrim Baptist Church in Charlottesville is getting ready to host a conference on Alzheimer's disease to raise awareness and help caregivers in the African-American community. Studies show African-Am... […]
- Alzheimer’s Disease and Exercise on February 19, 2019 at 6:05 am
sLeptin is back at it again! Since our group presented this week about the role of myokines in exercise, we thought it would only be appropriate to revisit the topic of exercise and further ... […]
- Could a blood test predict Alzheimer's disease 16 years before symptoms? on February 19, 2019 at 3:04 am
Could a blood test diagnose Alzheimer's disease up to 16 years before a person begins showing symptoms? The chief executive at Lexington-based Quanterix Corp. believes so. Clinical trial data publishe... […]
via Bing News